Bellaseno, a medtech company founded in Australia and now based in Leipzig, Germany, has accelerated human trials of its regenerative breast scaffold technology following a licensing and collaboration agreement with Mentor Worldwide, a Johnson and Johnson MedTech subsidiary.
The agreement, announced in early June 2026, is aimed at advancing regenerative soft tissue reconstruction and driving the technology toward commercialisation. As of July 2026, 30 women have undergone scaffold surgery across two separate trials.
Enrolment ramping up
A pivotal trial launched in January 2026 has enrolled 11 patients so far, with the company expecting that number to more than double by the end of August. The trials build on an earlier first in human safety study run between 2021 and 2023, which involved 19 patients.
Bellaseno's scaffolds are made from medical grade polycaprolactone and are seeded with a patient's own fat cells, acting as an absorbable framework that supports tissue regeneration over one to two years. In the first in human study, patients retained an average of 83 percent of breast volume at the two year follow up, with no major complications reported. Professor Anand Deva, who has led clinical work on the trials, said clinicians examining the results "would say they were simply looking at normal breast tissue."
